GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » 6-1 Month Momentum %

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) 6-1 Month Momentum % : N/A% (As of Jun. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-06-15), Infant Bacterial Therapeutics AB's 6-1 Month Momentum % is N/A%.

The industry rank for Infant Bacterial Therapeutics AB's 6-1 Month Momentum % or its related term are showing as below:

IFTBF's 6-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -5.57
* Ranked among companies with meaningful 6-1 Month Momentum % only.

Competitive Comparison of Infant Bacterial Therapeutics AB's 6-1 Month Momentum %

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's 6-1 Month Momentum % falls into.



Infant Bacterial Therapeutics AB  (GREY:IFTBF) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Infant Bacterial Therapeutics AB  (GREY:IFTBF) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Infant Bacterial Therapeutics AB 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Headlines

No Headlines